COMPANY PROFILE // THE 014 REPORT
Collegium Pharmaceutical, Inc.
COLL (Nasdaq)
Assembled from 4 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberGLEIF: the direct parent is not reported; reporting exception filed with reason NON_PUBLIC.
- AmberLEI 54930049FXZMTLW8D496 registration status is LAPSED (last update 2025-06-13): the legal-entity record has not been renewed.
✓ SEC filings✓ LEI✓ State registrationpossible match✓ Lobbying registrationpossible match✗ SAM registration✗ IRS return✗ Website
No SAM registration, no IRS return, no website on record.
COLLEGIUM PHARMACEUTICAL, INC is an SEC-registered operating company in pharmaceutical preparations, incorporated in VA, based in Stoughton, MA; listed as COLL (Nasdaq).[source] It reported revenue of $780.6 million for the fiscal year ended 2025-12-31.[source] It has filed 76 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-16.[source] 4 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are BlackRock, Inc., Jupiter Topco LLC, Invesco Ltd. (as of 2026-06-30).[source] Seraphix flags 2 items from these records: LEI 54930049FXZMTLW8D496 registration status is LAPSED (last update 2025-06-13); GLEIF.[source]
- red0
- amber2
- info0
- BlackRock, Inc.$197.0M
- Jupiter Topco LLC$77.7M
- Invesco Ltd.$68.1M
- FULLER & THALER ASSET MANAGEMENT, INC.$59.1M
- PRINCIPAL FINANCIAL GROUP INC$59.1M
- STATE STREET CORP$55.3M
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/$50.9M
- VANGUARD CAPITAL MANAGEMENT LLC$50.0M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Dieter David · EVP & General Counsel (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Dreyer Scott · EVP & Chief Commercial Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Karnani Vikram · President and CEO (Director,Officer) · latest Form 4 2026-02-12 · filing · LinkedIn search
- Smith Thomas B · EVP and Chief Medical Officer (Officer) · latest Form 4 2026-02-12 · filing · LinkedIn search
- Tupper Colleen · EVP & Chief Financial Officer (Officer) · latest Form 4 2026-02-12 · filing · LinkedIn search
- BOHLIN GAREN G · Director · latest Form 4 2025-05-19 · filing · LinkedIn search
- Balice-Gordon Rita J. · Director · latest Form 4 2025-12-09 · filing · LinkedIn search
- Fallon John A. · Director · latest Form 4 2025-11-14 · filing · LinkedIn search
- Freund John Gordon · Director · latest Form 4 2025-08-12 · filing · LinkedIn search
- Lurker Nancy · Director · latest Form 4 2025-05-19 · filing · LinkedIn search
- Paya Carlos V · Director · latest Form 4 2025-05-19 · filing · LinkedIn search
- SANTINI GINO · Director · latest Form 4 2025-08-19 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Troutman Pepper Locke LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-06-01
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001267565 | source |
| LEI | 54930049FXZMTLW8D496 | source |
| EIN | 00-0000000 | source |
| Connecticut business ID | 3293958 | record |
| LDA clientpossible match | 72757 | record |
| LDA clientpossible match | 71155 | record |
| LDA clientpossible match | 210995 | record |
| Business address (SEC) | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2018-05-18 · in -3,108 days · LEI next renewal (54930049FXZMTLW8D496)
- 2027-03-01 · in 101 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Dyne Therapeutics, Inc. · Karnani Vikram
- Karyopharm Therapeutics Inc. · BOHLIN GAREN G
- SI-BONE, Inc. · Freund John Gordon
- EyePoint, Inc. · Lurker Nancy
- Alkermes plc. · Lurker Nancy
- Vaxcyte, Inc. · Paya Carlos V
- COMPASS Pathways plc · SANTINI GINO
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-10-19 filing 8-K items 1.02 · SEC EDGAR
- 2026-09-30 filing 144 · SEC EDGAR
- 2026-08-13 filing 8-K items 8.01 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,7.01 · SEC EDGAR
- 2026-07-17 filing 144 · SEC EDGAR
- 2026-07-15 filing 144 · SEC EDGAR
- 2026-06-30 filing 8-K/A items 9.01 · SEC EDGAR
- 2026-06-01 filing S-8 · SEC EDGAR
- 2026-06-01 filing S-8 · SEC EDGAR
- 2026-05-18 filing 144 · SEC EDGAR
- 2026-05-15 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-15 filing 144 · SEC EDGAR
- 2026-05-13 filing 144 · SEC EDGAR
- 2026-05-12 officer change 8-K items 2.01,5.02,7.01,9.01 · SEC EDGAR
- 2026-05-11 filing 144 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-04-07 filing ARS · SEC EDGAR
- 2026-04-07 filing Proxy statement · SEC EDGAR
- 2026-04-07 officer change 8-K items 5.02 · SEC EDGAR
- 2026-03-19 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-03-18 filing 144 · SEC EDGAR
- 2026-03-09 filing 144 · SEC EDGAR
- 2026-03-03 filing 144 · SEC EDGAR
- 2026-02-26 filing Annual report (10-K) · SEC EDGAR
- 2026-02-26 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-02-12 insider First Form 3/4/5 on record for Dieter David (EVP & General Counsel) · SEC Forms 3/4/5
170 earlier entries
- 2026-01-08 filing 8-K items 7.01,9.01
- 2025-12-30 filing 8-K items 1.01,1.02,3.02,7.01,9.01
- 2025-12-17 filing 144
- 2025-12-08 filing 144
- 2025-11-14 insider First Form 3/4/5 on record for Karnani Vikram (President and CEO)
- 2025-11-12 filing 144
- 2025-11-07 insider First Form 3/4/5 on record for Tupper Colleen (EVP & Chief Financial Officer)
- 2025-11-06 filing 144
- 2025-11-06 filing Quarterly report (10-Q)
- 2025-11-06 filing 8-K items 2.02,7.01,9.01
- 2025-09-03 insider First Form 3/4/5 on record for Smith Thomas B (EVP and Chief Medical Officer)
- 2025-08-29 filing 144
- 2025-08-18 filing 144
- 2025-08-15 filing 144
- 2025-08-15 insider First Form 3/4/5 on record for Dreyer Scott (EVP & Chief Commercial Officer)
- 2025-08-13 filing 144
- 2025-08-07 filing Quarterly report (10-Q)
- 2025-08-07 filing 8-K items 2.02,7.01,9.01
- 2025-07-09 filing 144
- 2025-07-08 filing 144
- 2025-07-07 filing 144
- 2025-07-07 filing 8-K items 8.01
- 2025-07-02 filing 144
- 2025-07-02 filing 144
- 2025-06-09 filing 144
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8 POS
- 2025-06-06 filing S-8
- 2025-05-19 officer change 8-K items 5.02,5.07,9.01
- 2025-05-19 insider First Form 3/4/5 on record for BOHLIN GAREN G (Director)
- 2025-05-19 insider First Form 3/4/5 on record for Balice-Gordon Rita J. (Director)
- 2025-05-19 insider First Form 3/4/5 on record for Fallon John A. (Director)
- 2025-05-19 insider First Form 3/4/5 on record for Freund John Gordon (Director)
- 2025-05-19 insider First Form 3/4/5 on record for Lurker Nancy (Director)
- 2025-05-19 insider First Form 3/4/5 on record for Paya Carlos V (Director)
- 2025-05-19 insider First Form 3/4/5 on record for SANTINI GINO (Director)
- 2025-05-12 filing 8-K items 8.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,7.01,9.01
- 2025-03-28 filing DEFA14A
- 2025-03-28 filing ARS
- 2025-03-28 filing Proxy statement
- 2025-03-21 filing 144
- 2025-03-21 filing 144
- 2025-03-20 filing 144
- 2025-03-20 filing 144
- 2025-03-20 filing 144
- 2025-03-17 officer change 8-K items 5.02,8.01
- 2025-03-14 filing 144
- 2025-03-14 filing 144
- 2025-03-11 filing 144
- 2025-03-11 filing 144
- 2025-03-07 filing 144
- 2025-03-07 filing 144
- 2025-03-06 filing 144
- 2025-03-06 filing 144
- 2025-03-06 filing S-8
- 2025-03-06 filing 144
- 2025-03-05 filing 144
- 2025-03-04 filing 144
- 2025-02-27 filing Annual report (10-K)
- 2025-02-27 officer change 8-K items 2.02,5.02,7.01,9.01
- 2025-02-05 officer change 8-K items 5.02
- 2025-01-10 filing 144
- 2025-01-08 filing 8-K items 7.01,9.01
- 2024-11-14 filing 8-K/A items 9.01
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 officer change 8-K items 2.02,5.02,7.01,9.01
- 2024-09-13 filing 144
- 2024-09-13 filing 144
- 2024-09-06 filing 144
- 2024-09-05 filing 144
- 2024-09-04 filing 8-K items 2.01,2.03,7.01,9.01
- 2024-08-15 filing S-8
- 2024-08-12 filing 144
- 2024-08-09 filing 144
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,7.01,9.01
- 2024-07-29 officer change 8-K items 1.01,2.02,2.03,5.02,7.01,9.01
- 2024-06-13 filing 8-K items 8.01,9.01
- 2024-06-05 filing 144
- 2024-06-04 filing 144
- 2024-06-03 filing 144
- 2024-06-03 filing 144
- 2024-05-30 filing 144
- 2024-05-29 filing 144/A
- 2024-05-29 filing 144
- 2024-05-28 filing 144
- 2024-05-28 filing 144
- 2024-05-24 officer change 8-K items 5.02
- 2024-05-24 filing 144
- 2024-05-23 filing 144
- 2024-05-20 filing 8-K items 5.07
- 2024-05-14 filing 144
- 2024-05-13 filing 8-K items 8.01
- 2024-05-10 filing DEFA14A
- 2024-05-10 officer change 8-K items 5.02
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,7.01,9.01
- 2024-04-29 filing 8-K items 1.01
- 2024-04-11 filing 8-K items 8.01,9.01
- 2024-04-05 filing ARS
- 2024-04-05 filing DEFA14A
- 2024-04-05 filing Proxy statement
- 2024-02-29 filing 144
- 2024-02-26 filing 144
- 2024-02-22 filing Annual report (10-K)
- 2024-02-22 filing 8-K items 2.02,7.01,9.01
- 2024-01-16 filing 144
- 2024-01-03 filing 8-K items 7.01,8.01,9.01
- 2023-12-21 filing 144
- 2023-12-20 filing 144
- 2023-12-19 filing 144
- 2023-12-18 filing 144
- 2023-11-27 filing 144
- 2023-11-09 filing 8-K items 8.01
- 2023-11-07 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 2.02,7.01,9.01
- 2023-08-24 filing 8-K items 8.01,9.01
- 2023-08-10 filing S-8
- 2023-08-07 filing 8-K items 8.01
- 2023-08-03 filing 8-K items 2.02,7.01,9.01
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-06-26 filing 144
- 2023-06-02 filing 144
- 2023-06-01 filing 144
- 2023-05-31 filing 144
- 2023-05-30 filing 144
- 2023-05-19 filing 8-K items 5.07
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,7.01,9.01
- 2023-04-11 filing ARS
- 2023-04-11 filing Proxy statement
- 2023-03-15 filing 144
- 2023-03-01 filing 144
- 2023-02-23 filing Annual report (10-K)
- 2023-02-23 filing 8-K items 2.02,7.01,9.01
- 2023-02-13 filing 8-K items 1.01,2.03,3.02,8.01,9.01
- 2023-02-06 filing 8-K items 2.02,7.01,8.01,9.01
- 2023-01-04 filing 8-K items 7.01,8.01,9.01
- 2022-12-22 filing 8-K items 7.01,8.01,9.01
- 2022-11-03 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,7.01,9.01
- 2022-08-11 filing S-8
- 2022-08-04 filing Quarterly report (10-Q)
- 2022-08-04 filing 8-K items 2.02,7.01,9.01
- 2022-05-23 filing 8-K items 5.07
- 2022-05-13 filing 8-K/A items 9.01
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-10 filing 8-K items 2.02,7.01,9.01
- 2022-04-13 filing 8-K items 7.01,9.01
- 2022-04-06 filing DEFA14A
- 2022-04-06 filing Proxy statement
- 2022-04-06 officer change 8-K items 5.02
- 2022-04-05 filing 8-K items 7.01,9.01
- 2022-03-23 officer change 8-K items 1.01,2.01,2.03,5.02,8.01,9.01
- 2022-03-21 filing SC TO-T/A
- 2022-03-11 filing SC TO-T/A
- 2022-03-04 filing SC TO-T/A
- 2022-02-24 filing Annual report (10-K)
- 2022-02-24 filing 8-K items 2.02,9.01
- 2022-02-22 filing SC TO-T/A
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-05 (within 30 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-19 (older) 8-K filed: Item 1.02 agreement terminated
- 2026-08-13 (older) 8-K filed: Item 8.01 other event
- 2026-08-06 (older) 10-Q filed
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure
- 2026-06-30 (older) 8-K/A filed: Item 9.01 exhibits
- 2026-06-01 (older) S-8 filed (FORM S-8)
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:COLL The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
9 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1267565 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | COLL / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 54930049FXZMTLW8D496 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 54930049FXZMTLW8D496) | GLEIF |
| CUSIP | 19459J104 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001267565 | SEC EDGAR |
| UEI | DMDLZN7GH8R7 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001267565 | USAspending |
possible match: matched by name only, not merged (5)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $780,567,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 05:05 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $62,870,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 05:05 UTC | Report an error |
| Total assets (at 2025-12-31) | $1,656,834,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 05:05 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $301,675,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 05:05 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $231,252,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 05:05 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:05 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:05 UTC | Report an error |
| State of incorporation | VA | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:05 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:05 UTC | Report an error |
| Business address | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:05 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 05:05 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $329,323,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 05:05 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $1,740,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 05:05 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $5,539,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 05:05 UTC | Report an error |
| Form D total offering amount (D filed 2018-11-13) | $20,000,006 | 2018-11-13 | D | as filed | 2026-11-20 05:05 UTC | Report an error |
| Form D total amount sold (D filed 2018-11-13) | $20,000,006 | 2018-11-13 | D | as filed | 2026-11-20 05:05 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2018-11-13 | D | as filed | 2026-11-20 05:05 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2018-11-13 | D | as filed | 2026-11-20 05:05 UTC | Report an error |
| Form D date of first sale | 2018-11-08 | 2018-11-13 | D | as filed | 2026-11-20 05:05 UTC | Report an error |
| Federal award transactions, fiscal year 2026 (this one registration only) | $0 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-20 05:05 UTC | Report an error |
| Number of federal award transactions, fiscal year 2026 (this one registration only) | 5 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-20 05:05 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001628280-26-070589
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $216,339,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001628280-26-070589 | 2026-11-20 05:05 UTC | Report an error |
| Net income (loss) | $21,759,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001628280-26-070589 | 2026-11-20 05:05 UTC | Report an error |
| Interest expense | $21,943,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001628280-26-070589 | 2026-11-20 05:05 UTC | Report an error |
| Cash and cash equivalents | $144,797,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001628280-26-070589 | 2026-11-20 05:05 UTC | Report an error |
| Contract liabilities (total) | $10,393,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001628280-26-070589 | 2026-11-20 05:05 UTC | Report an error |
| Contract liabilities, current | $1,782,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001628280-26-070589 | 2026-11-20 05:05 UTC | Report an error |
| Contract liabilities, noncurrent | $8,611,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001628280-26-070589 | 2026-11-20 05:05 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-05 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-19 Filing 8-K filed: Item 1.02 agreement terminated
- 2026-08-13 Filing 8-K filed: Item 8.01 other event
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure
- 2026-06-30 Filing 8-K/A filed: Item 9.01 exhibits
- 2026-06-01 Filing S-8 filed (FORM S-8)
- 2026-06-01 Filing S-8 filed (FORM S-8)
- 2026-05-15 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-12 Filing 8-K filed: Item 2.01 acquisition or disposition; Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-07 Filing ARS filed
- 2026-04-07 Filing DEF 14A filed
- 2026-04-07 Filing 8-K filed: Item 5.02 officer or director change
- 2026-03-19 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-02-26 Filing 10-K filed
- 2026-02-26 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-01-08 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-12-30 Filing 8-K filed: Item 1.01 material agreement; Item 1.02 agreement terminated; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-11-06 Filing 10-Q filed
- 2025-11-06 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-08-07 Filing 10-Q filed
- 2025-08-07 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-05 8-K Item 2.02, Results of Operations and Financial Condition
On November 5, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended September 30, 2026. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K. the 8-K · retrieved 2026-11-20 05:05 UTC - 2026-11-05 8-K Item 7.01, Regulation FD Disclosure
On November 5, 2026, Collegium Pharmaceutical, Inc. released an earnings presentation. The presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K. the 8-K · retrieved 2026-11-20 05:05 UTC - 2026-10-19 8-K Item 1.02
Termination of a Material Definitive Agreement. As previously disclosed, Collegium Pharmaceutical, Inc. (the “Company”) is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH (“Grünenthal”) (as amended, the “Grünenthal License”) which the Company assumed pursuant to a Consent Agreement, dated as of January 30, 2020 between the Company, Grünenthal and Assertio Therapeutics, Inc. (the “Consent Agreement”) as part of the Company’s 2020 acquisition of Nucynta ER and Nucynta IR (the “Nucynta Products”). As also previously disclosed, in February 2026, Grünenthal filed a complaint in the United States District Court for the District of New Jersey, naming the… the 8-K · retrieved 2026-11-20 05:05 UTC - 2026-08-06 8-K Item 2.02, Results of Operations and Financial Condition
On August 6, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K. the 8-K · retrieved 2026-11-20 05:05 UTC - 2026-08-06 8-K Item 7.01, Regulation FD Disclosure
On August 6, 2026, Collegium Pharmaceutical, Inc. released an earnings presentation. The presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K. the 8-K · retrieved 2026-11-20 05:05 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
4 lobbying records carry this company's exact name, hiring 4 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (4)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCOLLEGIUM PHARMACEUTICAL INC. (lobbying via NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC) · exact legal name · sx:lda:72757 Compare
- possible matchCOLLEGIUM PHARMACEUTICAL, INC. (lobbying via SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA) · exact legal name · sx:lda:71155 Compare
- possible matchCOLLEGIUM PHARMACEUTICAL, INC. (lobbying via THORN RUN PARTNERS) · exact legal name · sx:lda:210995 Compare
- possible matchCOLLEGIUM PHARMACEUTICAL, INC. (lobbying via an individual registrant) · exact legal name · sx:lda:142669 Compare
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCOLLEGIUM PHARMACEUTICAL INC. · exact legal name · sx:epa:110070432047 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $196,971,512 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 2 | Jupiter Topco LLC | $77,743,493 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 3 | Invesco Ltd. | $68,146,464 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 4 | FULLER & THALER ASSET MANAGEMENT, INC. | $59,106,662 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 5 | PRINCIPAL FINANCIAL GROUP INC | $59,091,433 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 6 | STATE STREET CORP | $55,345,492 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 7 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $50,881,525 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $50,001,648 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 9 | RENAISSANCE TECHNOLOGIES LLC | $49,469,074 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
| 10 | EVENTIDE ASSET MANAGEMENT, LLC | $49,272,746 | 2026-06-30 | SEC 13F filing | 2026-11-20 05:05 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- Collegium Pharmaceutical, Inc. · LEI 54930049FXZMTLW8D496 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
4 state and city records carry this company's exact name, from 3 sources. Possible matches only.
State licences (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCOLLEGIUM PHARMACEUTICAL · exact name match to 'COLLEGIUM PHARMACEUTICAL, INC' (no other entity shares the name) · sx:elic:ctcred:2535261 Compare
- possible matchCOLLEGIUM PHARMACEUTICAL, INC. · exact legal name · sx:elic:ctcred:1352186 Compare
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCollegium Pharmaceutical Inc · exact legal name · sx:ctsos:3293958 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCollegium Pharmaceutical, Inc. · exact legal name · sx:ctgov:hf9e9109c7335a9de Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1267565.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001267565. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.